

February 4, 2015 - Frequently Asked Questions and Answers – (FAQs)

From time to time, Merck Investor Relations will provide FAQs on various topics of interest. The following are recent FAQs.

Key words: CUBICIN Full Year 2014 Sales

[What were CUBICIN Sales for Full Year 2014?](#)

**FULL YEAR 2014
(AMOUNTS IN MILLIONS)**

	Global	U.S.	International
CUBICIN SALES	\$1,046	\$977	\$69

DISCLOSURE NOTICE:

This FAQ contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2013.

Investor Contacts:
Justin Holko – 908-740-1879
Amy Klug – 908-740-1898